Cited by 402Advanced Breast Cancer TherapiesCancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 285 of the 292 references it cites were found in a registry or an index.

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Open access

Whittaker, Steven R., Mallinger, Aurélie, Workman, Paul, Clarke, Paul A.·2017·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2017.02.008PMC PMC6141011

Open this paper in CoChat — free account

Abstract

Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs). This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer. CDKs have now been shown to regulate other processes, particularly various aspects of transcription. The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers. The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors. However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest. Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER+/HER2- advanced breast cancer. Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compounds that have allowed exploration of individual CDKs as cancer targets and the determination of their potential therapeutic windows. Biomarkers that allow the selection of patients likely to respond are now being discovered. Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors. This suggests that the selective inhibitors may be best used combined with standard of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2017.02.008

Cites

285 of 285 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Cancer Cell Cycles
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Héry-Arnaud, G., Berre, R. L., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 5,008
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“In any case, RB remains phosphorylated throughout the S, G2 and M phases, and at the end of mitosis it is dephosphorylated by protein phosphatase 1 (Malumbres & Barbacid, 2009).”
The Role of Chromatin during Transcription
Li, B., Carey, M., & Workman, J. L. (2007) · Cell · doi:10.1016/j.cell.2007.01.015 · Cited by 3,503
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900

Show all 292 references

Sorted by citations

Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
Cell cycle control in cancer
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
The broken cycle: E2F dysfunction in cancer
Kent, L. N., & Leone, G. W. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 807
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Lin, A., Giuliano, C. J., Palladino, A. C., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8412 · Cited by 769
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
Ding, L., Cao, J., Lin, W.-S., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061960 · Cited by 655
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S. E., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 461
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry
Mäder, P., & Kattner, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00960 · Cited by 454
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 412
Interconnection between Metabolism and Cell Cycle in Cancer
Icard, P., Fournel, L., Wu, Z., Alifano, M., & Lincet, H. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.12.007 · Cited by 340
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y.-C., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 297
Aging of the cells: Insight into cellular senescence and detection Methods.
Mohamad Kamal, N. S., Safuan, S., Shamsuddin, S., & Foroozandeh, P. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151108 · Cited by 287
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, C. E., Tilley, W. D., & Wang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 285
CDK inhibitors in cancer therapy, an overview of recent development.
Zhang, M., Zhang, L., Hei, R., Li, X., Cai, H., Wu, X., Zheng, Q., & Cai, C. (2021) · PubMed Central · Cited by 280
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives
Ali, E. S., Sharker, S. M., Islam, M. T., Khan, I. N., Shaw, S., Rahman, M. A., Uddin, S. J., Shill, M. C., Rehman, S., Das, N., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.011 · Cited by 281
Structural insights into the functional diversity of the CDK–cyclin family
Wood, D. J., & Endicott, J. (2018) · Open Biology · doi:10.1098/rsob.180112 · Cited by 272
CDK7 inhibitors as anticancer drugs
Sava, G. P., Fan, H., Coombes, R. C., Buluwela, L., & Ali, S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09885-8 · Cited by 200
An OFF–ON Two-Photon Fluorescent Probe for Tracking Cell Senescence in Vivo
Lozano‐Torres, B., Galiana, I., Rovira, M., Garrido, E. M. N., Chaib, S., Bernardos, A., Muñoz‐Espín, D., Serrano, M., Martínez‐Máñez, R., & Sancenón, F. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b04985 · Cited by 185
Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition
Wood, D. J., Korolchuk, S., Tatum, N. J., Wang, L.-Z., Endicott, J., Noble, M. E. M., & Martin, M. P. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.015 · Cited by 176
Cancer Hallmarks and MicroRNAs: The Therapeutic Connection
Roosbroeck, K. V., & Călin, G. A. (2017) · Advances in cancer research · doi:10.1016/bs.acr.2017.06.002 · Cited by 164
Small-molecule targeting of brachyury transcription factor addiction in chordoma
Sharifnia, T., Wawer, M. J., Chen, T., Huang, Q., Weir, B. A., Sizemore, A. E., Lawlor, M. A., Goodale, A. B., Cowley, G. S., Vázquez, F., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0312-3 · Cited by 159
Self-citation
Modulating inflammation for cancer therapy
Ritter, B., & Greten, F. R. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181739 · Cited by 162
CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents
Anshabo, A. T., Milne, R. W., Wang, S., & Albrecht, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.678559 · Cited by 155
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Yuan, K., Wang, X., Dong, H., Min, W., Hao, H., & Yang, P. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.05.001 · Cited by 148
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 145
Recent Advances of Molecular Optical Probes in Imaging of β-Galactosidase
Zhang, J., Cheng, P., & Pu, K. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00391 · Cited by 137
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update
Wu, T., Qin, Z., Tian, Y., Wang, J., Xu, C., Li, Z., & Bian, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00744 · Cited by 119
Quantifying CDK inhibitor selectivity in live cells
Wells, C. I., Vasta, J. D., Corona, C. R., Wilkinson, J., Zimprich, C., Ingold, M. R., Pickett, J. E., Drewry, D. H., Pugh, K., Schwinn, M. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16559-0 · Cited by 119
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities
Jiang, X., Wu, K., Bai, R., Zhang, P., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114085 · Cited by 115
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures
Cheng, W., Yang, Z., Wang, S., Li, Y., Han, W., Tian, X., & Kan, Q. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.003 · Cited by 111
Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations
Eldehna, W. M., Hassab, M. A. E., Abo-Ashour, M. F., Al-Warhi, T. I., Elaasser, M. M., Safwat, N. A., Suliman, H. S., Ahmed, M. F. E., Al‐Rashood, S. T., Abdel‐Aziz, H. A., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104748 · Cited by 109
Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
Górecki, L., Andrš, M., & Korábečný, J. (2021) · Cancers · doi:10.3390/cancers13040795 · Cited by 107
Pyrimidine: An elite heterocyclic leitmotif in drug discovery‐synthesis and biological activity
Nadar, S., & Khan, T. A. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14001 · Cited by 95
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer
Frame, S., Saladino, C., MacKay, C., Atrash, B., Sheldrake, P. W., McDonald, E., Clarke, P. A., Workman, P., Blake, D., & Zheleva, D. I. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234103 · Cited by 94
Self-citation
Integrative Bioinformatics Approaches to Map Potential Novel Genes and Pathways Involved in Ovarian Cancer
Kumar, S. U., Kumar, D. T., Ramamoorthy, S., Doss, C. G. P., & Zayed, H. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00391 · Cited by 87
The Hippo Signaling Pathway in Cancer: A Cell Cycle Perspective
Xiao, Y., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13246214 · Cited by 84
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
Manzotti, G., Ciarrocchi, A., & Sancisi, V. (2019) · Cancers · doi:10.3390/cancers11030304 · Cited by 84
Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma
Song, X., Liu, X., Wang, H., Wang, J., Qiao, Y., Cigliano, A., Utpatel, K., Ribback, S., Pilo, M. G., Serra, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0284 · Cited by 87
Development of CDK2 and CDK5 Dual Degrader TMX‐2172
Teng, M., Jiang, J., He, Z., Kwiatkowski, N. P., Donovan, K. A., Mills, C. E., Victor, C., Hatcher, J. M., Fischer, E. S., Sorger, P. K., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004087 · Cited by 82
miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14
Ji, Q., Xu, X., Li, L., Goodman, S. B., Bi, W., Xu, M., Xu, Y., Fan, Z., Maloney, W. J., Ye, Q., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.499 · Cited by 82
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
Diab, S., Yu, M., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01985 · Cited by 81
Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer (Review)
Sen, P., Ganguly, P., & Ganguly, N. (2017) · Oncology Letters · doi:10.3892/ol.2017.7292 · Cited by 77
Computational analysis of protein-ligand interaction by targeting a cell cycle restrainer
Singh, R., & Purohit, R. (2023) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2023.107367 · Cited by 74
The Nitrogen Mustards
Highley, M., Landuyt, B., Prenen, H., Harper, P., & de Bruijn, E. A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000121 · Cited by 79
Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors
Cherukupalli, S., Chandrasekaran, B., Kryštof, V., Aleti, R. R., Sayyad, N., Merugu, S. R., Kushwaha, N. D., & Karpoormath, R. V. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.02.030 · Cited by 70
Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors
El‐Naggar, A. M., El-Hashash, M. A. A., & Elkaeed, E. B. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104615 · Cited by 68
Advances in pyrazolo[1,5- a ]pyrimidines: synthesis and their role as protein kinase inhibitors in cancer treatment
Iorkula, T. H., Osayawe, O. J.-K., Odogwu, D. A., Ganiyu, L. O., Faderin, E., Awoyemi, R. F., Akodu, B. O., Ifijen, I. H., Aworinde, O. R., Agyemang, P., et al. (2025) · RSC Advances · doi:10.1039/d4ra07556k · Cited by 70
Modulation of Hair Growth Promoting Effect by Natural Products
Park, S., & Lee, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122163 · Cited by 71
The era of high-quality chemical probes
Licciardello, M. P., & Workman, P. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00291d · Cited by 61
Self-citation
The acid-base transport proteins NHE1 and NBCn1 regulate cell cycle progression in human breast cancer cells
Flinck, M., Kramer, S. H., Schnipper, J., Andersen, A. P., & Pedersen, S. F. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1464850 · Cited by 61
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer
Reck, M., Horn, L., Novello, S., Barlési, F., Albert, I., Juhász, E., Kowalski, D. M., Robinet, G., Cadranel, J. L., Bidoli, P., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.010 · Cited by 61
CDK15 promotes colorectal cancer progression via phosphorylating PAK4 and regulating β-catenin/ MEK-ERK signaling pathway
Huang, C., Du, R., Jia, X., Liu, K., Qiao, Y., Wu, Q., Yao, N., Yang, L., Zhou, L., Liu, X., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00828-6 · Cited by 60
Targeting bromodomain and extraterminal proteins in breast cancer
Sahni, J. M., & Keri, R. A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.015 · Cited by 61
Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer
Mills, C. C., Kolb, E. A., & Sampson, V. B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2066 · Cited by 59
Paradigm shift of “classical” HDAC inhibitors to “hybrid” HDAC inhibitors in therapeutic interventions
Vaidya, G. N., Rana, P., Venkatesh, A., Chatterjee, D. R., Contractor, D., Satpute, D. P., Nagpure, M., Jain, A. K., & Kumar, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112844 · Cited by 60
Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia
Almehmadi, S. J., Alsaedi, A. M. R., Harras, M. F., & Farghaly, T. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105431 · Cited by 59
Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling
Yao, J., Xu, S. Q., Sun, Y., Xu, Y., Guo, Q., & Wei, L. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00708-2 · Cited by 56
Distinct states of nucleolar stress induced by anticancer drugs
Potapova, T., Unruh, J. R., Conkright-Fincham, J., Banks, C. A. S., Florens, L. A., Schneider, D. A., & Gerton, J. L. (2023) · eLife · doi:10.7554/elife.88799 · Cited by 60
Synthesis of 4,6-disubstituted pyrazolo[3,4-d]pyrimidine analogues: Cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation
Cherukupalli, S., Chandrasekaran, B., Aleti, R. R., Sayyad, N., Hampannavar, G. A., Merugu, S. R., Rachamalla, H. K., Banerjee‬‬‬‬‬‬‬‬‬, R., & Karpoormath, R. V. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.08.104 · Cited by 56
A Two-Photon Probe Based on Naphthalimide-Styrene Fluorophore for the In Vivo Tracking of Cellular Senescence
Lozano‐Torres, B., Blandez, J. F., Galiana, I., Lopez-Dominguez, J. A., Rovira, M., Pàez‐Ribes, M., González‐Gualda, E., Muñoz‐Espín, D., Serrano, M., Sancenón, F., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c05447 · Cited by 52
Structure-based discovery of cyclin-dependent protein kinase inhibitors
Martin, M. P., Endicott, J., & Noble, M. E. M. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170040 · Cited by 53
Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future
Chen, X., Xu, D., Li, X., Zhang, J., Xu, W., Hou, J., Zhang, W., & Tang, J. (2019) · Journal of Cancer · doi:10.7150/jca.33079 · Cited by 53
A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents
Marak, B. N., Dowarah, J., Khiangte, L., & Singh, V. P. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112571 · Cited by 53
RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors
Kohlmeyer, J. L., Kaemmer, C. A., Pulliam, C. F., Maharjan, C. K., Samayoa, A. M., Major, H. J., Cornick, K. E., Knepper-Adrian, V., Khanna, R., Sieren, J. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2706 · Cited by 52
Development and utilization of human decidualization reporter cell line uncovers new modulators of female fertility
Haller, M., Yin, Y., & Ma, L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907652116 · Cited by 52
Alkaloids and Colon Cancer: Molecular Mechanisms and Therapeutic Implications for Cell Cycle Arrest
Khan, H. Z., Alam, W., Alsharif, K. F., Aschner, M., Pervez, S., & Saso, L. (2022) · Molecules · doi:10.3390/molecules27030920 · Cited by 53
A renal clearable fluorogenic probe for in vivo β-galactosidase activity detection during aging and senolysis
Rojas-Vázquez, S., Lozano‐Torres, B., García‐Fernández, A., Galiana, I., Pérez‐Villalba, A., Martí‐Rodrigo, P., Palop, M. J., Domínguez, M., Orzáez, M., Sancenón, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44903-1 · Cited by 53
Novel insights in cell cycle dysregulation during prostate cancer progression
Ben‐Salem, S., & Venkadakrishnan, V. B. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0517 · Cited by 52
CCRK is a novel signalling hub exploitable in cancer immunotherapy
Mok, M. T. S., Zhou, J., Tang, W., Zeng, X., Oliver, A. W., Ward, S. E., & Cheng, A. S. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.008 · Cited by 48
The Role of CDK5 in Tumours and Tumour Microenvironments
Do, P. A., & Lee, C. H. (2020) · Cancers · doi:10.3390/cancers13010101 · Cited by 49
Synthesis, docking, MD simulation, ADMET, drug likeness, and DFT studies of novel furo[2,3-b]indol-3a-ol as promising Cyclin-dependent kinase 2 inhibitors
Gheidari, D., Mehrdad, M., & Bayat, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-53514-1 · Cited by 51
The Cytomegalovirus Protein Kinase pUL97: Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting
Steingruber, M., & Marschall, M. (2020) · Microorganisms · doi:10.3390/microorganisms8040515 · Cited by 45
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline
Bhurta, D., & Bharate, S. B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21856 · Cited by 47
De Novo Molecule Design Using Molecular Generative Models Constrained by Ligand–Protein Interactions
Zhang, J., & Chen, H. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00177 · Cited by 44
Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer
Cho, J. M., Johnson, D. E., & Grandis, J. R. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.08.005 · Cited by 45
Undariopsis peterseniana Promotes Hair Growth by the Activation of Wnt/β-Catenin and ERK Pathways
Kang, J.-I., Kim, M. K., Lee, J., Jeon, Y., Hwang, E.-K., Koh, Y., Hyun, J. W., Kwon, S.-Y., Yoo, E.-S., & Kang, H. (2017) · Marine Drugs · doi:10.3390/md15050130 · Cited by 42
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
Tibes, R., & Bogenberger, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01205 · Cited by 42
A dual-enzyme activated fluorescent probe for precise identification of tumor senescence
Luo, X., Hu, E., Deng, F., Zhang, C., & Xian, Y. (2025) · Chemical Science · doi:10.1039/d5sc00103j · Cited by 41
Molecular profiling and combinatorial activity of CCT 068127: a potent CDK 2 and CDK 9 inhibitor
Whittaker, S. R., Barlow, C., Martin, M. P., Mancusi, C., Wagner, S., Self, A. J., Barrie, E., Poele, R. T., Sharp, S. Y., Brown, N., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12148 · Cited by 41
Self-citation
Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines
Rath, B., Hochmair, M. J., Plangger, A., & Hamilton, G. (2018) · Marine Drugs · doi:10.3390/md16100383 · Cited by 41
Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity
Wang, J., Li, T., Zhao, T., Wu, T., Liu, C., Ding, H., Li, Z., & Bian, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.024 · Cited by 40
A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
Somarelli, J. A., Roghani, R. S., Moghaddam, A. S., Thomas, B. C., Rupprecht, G., Ware, K. E., Altunel, E., Mantyh, J. B., Kim, S. Y., McCall, S. J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0454 · Cited by 39
Polyomavirus T Antigen Induces APOBEC3B Expression Using an LXCXE-Dependent and TP53-Independent Mechanism
Starrett, G. J., Serebrenik, A. A., Roelofs, P. A., Verhalen, B., McCann, J. L., Jarvis, M. C., Stewart, T. A., Law, E. K., Krupp, A., Jiang, M., et al. (2019) · mBio · doi:10.1128/mbio.02690-18 · Cited by 40
CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas
Cassandri, M., Fioravanti, R., Pomella, S., Valente, S., Rotili, D., Baldo, G. D., Angelis, B. D., Rota, R., & Mai, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01230 · Cited by 39
Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers
Sherbiny, F. F., Bayoumi, A. H., El-morsy, A., Sobhy, M., & Hagras, M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105325 · Cited by 38
Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases
Zhang, C., Stockwell, S. R., Elbanna, M., Ketteler, R., Freeman, J., Al‐Lazikani, B., Eccles, S. A., Brandon, A. D. H., Raynaud, F. I., Hayes, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0850-2 · Cited by 37
Self-citation
A Computational approach to discover potential quinazoline derivatives against CDK4/6 kinase
Anant, A., Ali, A., Ali, A., Gupta, G. D., & Asati, V. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131079 · Cited by 37
Garlic-derived bioactive compound S-allylcysteine inhibits cancer progression through diverse molecular mechanisms
Agbana, Y. L., Ni, Y., Zhou, M., Zhang, Q., Kassegne, K., Karou, S. D., Kuang, Y., & Zhu, Y. (2019) · Nutrition Research · doi:10.1016/j.nutres.2019.11.002 · Cited by 38
Getting under the skin: The role of CDK4/6 in melanomas
Guo, L., Qi, J., Wang, H., Jiang, X. L., & Liu, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112531 · Cited by 37
Micro-Current Stimulation Has Potential Effects of Hair Growth-Promotion on Human Hair Follicle-Derived Papilla Cells and Animal Model
Hwang, D., Lee, H., Lee, J., Lee, M., Cho, S., Kim, T., & Kim, H. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094361 · Cited by 37
Targeting CDK2 for cancer therapy
Knudsen, E. S., Witkiewicz, A. K., Sanidas, I., & Rubin, S. M. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116140 · Cited by 38
CDK1 serves as a novel therapeutic target for endometrioid endometrial cancer
Ying, X., Che, X., Wang, J., Zou, G., Yu, Q., & Zhang, X. (2021) · Journal of Cancer · doi:10.7150/jca.51139 · Cited by 35
Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy
Liu, Y., Fu, L., Wu, J., Liu, M., Wang, G., Liu, B., & Zhang, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114056 · Cited by 38
Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer
Xi, C., Wang, L., Yu, J., Ye, H., Cao, L., & Gong, Z. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.014 · Cited by 34
Vanillic Acid Stimulates Anagen Signaling via the PI3K/Akt/ β-Catenin Pathway in Dermal Papilla Cells
Kang, J.-I., Choi, Y. K., Koh, Y., Hyun, J. W., Kang, J., Lee, K., Lee, C. M., Yoo, E.-S., & Kang, H. (2020) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2019.206 · Cited by 37
Targeting CDK7 in oncology: The avenue forward
Li, Z., Liu, G., Gao, Y., & Zhao, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108229 · Cited by 34
The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region
Agnew, C., Liu, L., Liu, S., Xü, W., You, L., Yeung, W., Kannan, N., Jablons, D. M., & Jura, N. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009725 · Cited by 33
CDK7 Inhibition Is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition
McDermott, M. S. J., Sharko, A. C., Munie, J., Kassler, S., Melendez, T., Lim, C., & Broude, E. V. (2020) · Cells · doi:10.3390/cells9030638 · Cited by 33
Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
Hu, C., Shen, L., Zou, F., Wu, Y., Wang, B., Wang, A., Wu, C., Wang, L., Liu, J. L., Wang, W., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.026 · Cited by 34
Flavonoids Effects on Hepatocellular Carcinoma in Murine Models: A Systematic Review
García, E. R., Alviárez-Gutierrez, E., de Melo, F. C. S. A., Novaes, R. D., & Gonçalves, R. V. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/6328970 · Cited by 32

Authors: Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A.
Affiliations: Institute of Cancer Research (GB)
Corresponding author: Clarke, Paul A.
ORCID: Whittaker, Steven R.
Workman, Paul
Clarke, Paul A.
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2017-05
Volume: 173
Pages: 83-105
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2017.02.008
PMC: PMC6141011
OpenAlex: W2583136106
Cited by: 384
References: 292
Citations by year: 2026: 25 · 2025: 38 · 2024: 37 · 2023: 47 · 2022: 38 · 2021: 53 · 2020: 55 · 2019: 51 · 2018: 25 · 2017: 15
FWCI: 7.38
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Cancer Research UK (C309/A11566, C368/A6743, A368/A7990)
Topics: Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: cyclin-dependent kinases, cyclin-dependent kinase inhibitors, isoform-selective inhibitors, CDK4/6 inhibitors, palbociclib, breast cancer, cell cycle regulation, tumor cell proliferation, biomarkers, drug resistance, combination therapy, protein kinase inhibitors
MeSH terms: Animals, Antineoplastic Agents, Cell Cycle, Humans, Neoplasms, Drug Design, Cyclin-Dependent Kinases, Protein Kinase Inhibitors, Cell Proliferation, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks